In a retrospective cohort study of 123 patients with advanced non-small cell lung cancer (NSCLC) who received Osimertinib, the first third-generation EGFR-TKI, the incidence of cardiac AEs was 4.9% (118). Here, EGFR is linked to non-small cell lung carcinoma.